Sickle Cell Disease: Targeting Alloantibody formation Reduction; RIsk factors, aNd Genetics

Recruiting

• Conditions: Sickle Cell Anemia; Sickle Cell Disease; 10018902; 10005330

• Registration Number: NL-OMON50758
• Lead Sponsor: Sanquin Bloedbank

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 150

Inclusion Criteria

Sickle Cell disease patient
Need for transfusion
No alloantibodies

Exclusion Criteria

>25 transfusions
Chronic transfusion scheme

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The following determinants will be studied:<br /><br>Time dependent clinical risk factors and genetic risk factors for<br /><br>alloimmunization in SCD patients.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Response of the innate and adaptive immune system on a blood transfusion in<br /><br>responders (patients that form allo-antibodies) and non- responders (patients<br /><br>that don*t form allo-antibodies)</p><br>